MMP-9-IN-1 是一种特异性的基质金属蛋白酶-9 (MMP-9) 抑制剂,选择性靶向 MMP-9 的血红素 (PEX) 域,但不作用于其他 MMP。
生物活性 | MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which
selectively target the hemopexin (PEX) domain ofMMP-9, but not other MMPs[1]. |
IC50& Target[1] | |
体外研究 (In Vitro) | MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity[1]. MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells[1].
Cell Cytotoxicity Assay[1] Cell Line: | COS-1 monkey epithelial cell lines | Concentration: | 100 μM | Incubation Time: | 24 hours | Result: | Treatment did not cause notable cytotoxicity. |
Cell Proliferation Assay[1] Cell Line: | HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9 | Concentration: | 10 μM | Incubation Time: | 9 days | Result: | Significant inhibition of cell proliferation. |
|
体内研究 (In Vivo) | MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor[1]. MMP-9-IN-1 inhibits cancer cell metastasis in vivo[1].
Animal Model: | 4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor[1] | Dosage: | 20 mg/kg | Administration: | Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks, | Result: | Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 125 mg/mL(338.40 mM;Need ultrasonic) 配制储备液 1 mM | 2.7072 mL | 13.5358 mL | 27.0717 mL | 5 mM | 0.5414 mL | 2.7072 mL | 5.4143 mL | 10 mM | 0.2707 mL | 1.3536 mL | 2.7072 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 50% PBS Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (5.63 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。
*以上所有助溶剂都可在本网站选购。 |